Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.59 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28068467 | 0.86 | TMIGD3 (0.77) | ADORA3ADORA2AADORA1ADORA2BTMIGD3 | |
| SCHEMBL3049180 | 0.85 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL3055654 | 0.85 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL29501856 | 0.85 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL29501915 | 0.84 | ADORA2A (0.53) | ADORA3ADORA2AADORA1ADORA2BTMIGD3 | |
| SCHEMBL22349409 | 0.84 | CDK1 (0.73) | ADORA3ADORA2AADORA1 | |
| SCHEMBL29501881 | 0.84 | CDK1 (0.73) | ADORA3ADORA2AADORA1 | |
| SCHEMBL29703267 | 0.79 | PPARG (0.76) | ADORA3ADORA2AADORA1 | |
| SCHEMBL29703231 | 0.79 | PPARG (0.76) | ADORA3ADORA2AADORA1 | |
| SCHEMBL29703233 | 0.79 | PPARG (0.76) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115218-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2026-04-30 | — | — | US | disclosed |
| US-12213990-B2 | A3 adenosine receptor ligand for use for achieving a fat loss effect | CAN-FITE BIOPHARMA LTD. (IL) | 2025-02-04 | — | — | US | disclosed |
| EP-3530273-B1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN THE TREATMENT OF A SEXUAL DYSFUNCTION | CAN FITE BIOPHARMA LTD (IL) | 2024-08-14 | — | — | EP | disclosed |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| US-11291681-B2 | Method for treating fibrotic liver tissue using Cl-IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2022-04-05 | — | — | US | disclosed |
| US-20220079968-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | CAN-FITE BIOPHARMA LTD. (IL) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291681-B2 | Method for treating fibrotic liver tissue using Cl-IB-MECA | GPR119, FABP1, INSR | ADORA3 12/4885ADORA2A 4/4885ADORA1 18/4885 |
| US-20220079968-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | ADORA2A, ADORA3, FABP4 | ADORA3 2/4885ADORA2A 1/4885ADORA1 4/4885 |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20260115218-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA2B, ADORA3, ADORA2A | ADORA3 2/4885ADORA2A 3/4885ADORA1 4/4885 |
| US-12213990-B2 | A3 adenosine receptor ligand for use for achieving a fat loss effect | ADORA3, ADORA2A, FABP4 | ADORA3 1/4885ADORA2A 2/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.